Who’s acquiring who? Orphan designated drugs M&A activity in the pharmaceutical industry decreased by 23% in Q1 2023
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 20 pharmaceutical deals announced in…
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 20 pharmaceutical deals announced in Q1 2023, worth a total value of $50.2bn. The $43bn acquisition of Seagen by Pfizer was the industry’s largest disclosed deal. GlobalData’s New Drug Approvals and Their Contract Manufacture report provides critical insight into the contract manufacturing organization (CMO) industry by analysing relative performance of major CMOs by number of drug and vaccine approvals, and the outsourcing propensity for New Molecular Entities (NMEs) includin Buy the report here.
In value terms, orphan designated drugs-related deal activity increased by 58% in Q1 2023 compared with the previous quarter’s total of $31.8bn and rose by 1506% as compared to Q1 2022. Related deal volume decreased by 23% in Q1 2023 versus the previous quarter and was 5% higher than in Q1 2022.
The top-ranked financial advisors supporting these M&A deals in Q1 2023 were Centerview Partners; Bank of America; FTI Consulting with 4, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q1 2023 were Cooley; Fried, Frank, Harris, Shriver & Jacobson; Gibson, Dunn & Crutcher with 2, 2, 2 deals respectively.
For further understanding of GlobalData's New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.
What's Your Reaction?
